new data findings/day
patient tests analyzed
Real time access and analysis of over 40 genomic and clinical databases covering over 33,000 diseases.
Join us at an event or attend a webinar to learn how our products, solutions and services are empowering customers around the world to unlock valuable molecular insights.
Evidence based research, services and advanced software for better decisions.
New performance enhancements and 340,000+ mutation entries The Fall 2021 Release of the Human Gene ...
Food and feed safety is a main concern for food authorities, centers of disease control, departments...
Basic pathway analysis has several limitations that can slow down research progress and hinder insig...
We are very pleased to announce the latest QCI Interpret software release is now available. Expandin...
The recent plugin update to QIAGEN CLC Genomics version 21 (v21) includes new tools and database acc...
Now Available: HGMD Professional 2021.3
The use of NGS in food and feed safety
QIAGEN IPA Analysis Match now includes over 100,000 analyses to help advance your research
QCI Interpret Release 2021
Learn what’s new in the latest update to QIAGEN CLC Genomics version 21
Targeted NGS panels and optimized analysis and interpretation tools.
Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics services that ensure high-quality results.
Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.
Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.
QIAGEN maintains the world’s largest, expert-curated knowledgebase of up-to-date evidence for discovery research, clinical test interpretation and pharmaceutical development.
Interpretation of gene expression data to tackle inflammatory bowel disease
In Germany, scientists tackle cancer cohorts with Sample to Insight QIAGEN tools.
Mount Sinai's novel biomarker predicts treatment outcome in ovarian cancer